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Abstract: Temsirolimus is a potent inhibtor of the mammalian target of rapamycin (mTOR). 
In various clinical trials temsirolimus has shown an overall survival benefit for patients with 
metastatic renal cell carcinoma (mRCC). Thus it is approved for first-line therapy in high-risk 
mRCC patients. We discuss the indication, side effects and clinical implications of temsirolimus 
treatment.
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Introduction
Renal cell carcinoma (RCC) is the most common malignancy of the functional renal 
tissue, except the renal urothelium. RCC has an increasing incidence – an estimated 
209,000 patients are being diagnosed with cancer of the kidney and renal pelvis per 
year worldwide, and of these, 102,000 will die. Only 62% of all RCC patients survive 
5 years in all stages.1
According to the Heidelberg classification, RCC is divided into several distinct 
histological subtypes of different tumor entities. Most common are clear cell carcinomas 
(70% to 80%), papillary RCC (10% to 15%), divided into type I and type II papillary 
RCC, chromophobe (2% to 4%) carcinomas of the collecting ducts of Bellini (CDC) 
(0.6% to 1.2%) and unclassified RCC.
At initial presentation approximately 30% of the patients do have synchronous 
metastatic spread of the disease (mRCC). Another 40% will develop metachronous 
metastatic spread.1
RCC is highly vascularized, thus angiogenic therapy has shown high efficacy in 
the treatment of this disease. The multi-tyrosine-kinase inhibitors (TKIs) sunitinib and 
sorafenib, the mammalian target of rapamycin (mTOR) inhibitors temsirolimus and 
everolimus, and the VEGF-antagonist bevacizumab in combination with interferon 
alpha are available for systemic treatment of mRCC.
With angiogenic treatment based on sunitinib, sorafenib and temsirolimus, 
progression-free survival (PFS) was mostly doubled, and overall survival (OS) seemed 
to be prolonged.2–5 Thus, angiogenic treatment is regarded as standard therapy in 
metastatic patients without further surgical treatment choices.
mTOr inhibition
mTOR, a 250 kD protein kinase, has a key role in regulating translation of transcripts 
within the processes of angiogenesis and cell growth. Especially, hypoxia-inducible OncoTargets and Therapy 2010:3 192
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factor (HIF) alpha subunits are regulated by mTOR. 
Regulated by the PTEN/PI3-AKT pathway, mTOR also 
induces cyclin D1 and cMyc. mTOR inhibition has a direct 
cytostatic effect by blocking cellular progression from the 
G1 to the S phase.
Temsirolimus is a propyl ester analog of sirolimus, 
also known as rapamycin, a macrolide with antifungal and 
antitumor properties. Like the parent compound sirolimus, 
temsirolimus inhibits mTOR. Sirolimus is known as an oral 
immune-suppressor in transplant patients and has a well 
known pharmacologic profile. Temsirolimus iv is approved 
for first-line oncologic patients with poor risk classification, 
as shown in Table 1.
Study results with temsirolimus
In a single-agent, phase II study, temsirolimus administration 
to heavily pretreated patients with mRCC (n = 111) resulted 
in a median overall survival of 15.0 months.6 Retrospectively, 
49 patients were categorized in a poor-risk group according 
to Memorial Sloan Kettering Cancer Center (MSKCC) risk 
criteria.7 The temsirolimus-treated patients in this group had 
a 1.7-fold longer median OS than the first-line, interferon 
alpha (IFN)-treated, poor-risk group reported by Motzer 
et al.6,7 Thus, a phase III study in first-line, poor-risk mRCC 
patients was initiated in July 2003.
In this large multicenter phase III trial temsirolimus was 
tested in 626 patients with previously untreated mRCC. 
In a three-arm study, the combination of temsirolimus 
(15 mg iv weekly) and IFN (6 million U) was tested against 
temsirolimus (25 mg iv weekly) and IFN (18 million U) alone. 
The primary endpoint of a prolonged OS was reached, with 
patients who received temsirolimus alone having a longer OS 
(hazard ratio for death, 0.73; 95% confidence interval [CI], 
0.58 to 0.92; P = 0.008) and PFS (P  0.001) than patients 
who received IFN alone. OS in the combination-therapy 
group did not differ significantly from that in the IFN group. 
Median OS in the IFN group, the temsirolimus group, and the 
combination-therapy group were 7.3, 10.9, and 8.4 months, 
respectively.4 Although statistically not significant, even the 
combination of a dose-reduced temsirolimus therapy was 
beneficial in terms of improved OS than IFN alone.
Patients included had to be high-risk patients by 
modified MSKCC risk factor as defined by Motzer et al.8 
Three of 6 criteria had to be fulfilled for the inclusion of 
patients: a disease-free interval (DFI) of less than a year 
(time between initial diagnosis and metastatic spread), 
a Karnofsky performance status of 60% to 70%, a hemo-
globin level below the lower level of normal, a corrected 
calcium of more than 10 mg/dL (2.5 mmol/L), a lac-
tate-dehydrogenase (LDH) level of more than 1.5-fold the 
upper level of normal and more than one organ system with 
metastatic lesions (see Table 1). Three of these 6 parameters 
have to be fulfilled to classify a patient in the high-risk group 
suitable for temsirolimus therapy.
The IFN-only group received IFN at a starting dose of 
3 million U given subcutaneously 3 times per week for the 
first week. The dose was raised to 9 million U 3 times per 
week for the second week and to 18 million U 3 times per 
week for week 3, if this dose was tolerated. Thus the dose 
density was limited in the majority of the patients.
Nephrectomy
A subgroup analysis of the phase III trial was performed to 
estimate the implication of nephrectomy status in temsirolimus-
treated patients. Of the 626 patients, 419 (67%) underwent 
nephrectomy in the course of their disease prior to study 
inclusion. The results of this analysis presented at the 
2008 ASCO Annual Meeting showed a difference in OS of 
10.4 with nephrectomy vs 11.5 months without nephrec-
tomy, but the difference did not reach statistical significance 
(P = 0.2).9 With IFN treatment a slight benefit for OS was 
seen, with nephrectomy patients surviving 7.8 months after 
nephrectomy vs 6.2 months without nephrectomy. But again 
the difference was statistically insignificant (P = 0.47).
It remains unclear whether the effect is cause by the neph-
rectomy itself or by the patient selection, as risk stratification 
for randomization of the patients was done according to con-
sideration of nephrectomy status. Additionally, there is a lack 
of information about whether the nephrectomized patients 
were included with metachronous or synchronous metatastic 
disease. A Cox regression analysis to identify the factors 
that might contribute to this effect is still pending. Although 
proven for non-poor risk patients, in poor-prognosis patients, 
Table 1 Risk factors for the stratification of high-risk patients 
according to the modified criteria used as inclusion criteria for 
high-risk patients with temsirolimus treatment4 disease-free interval 
of less than a year
•    Karnofsky performance index between 60% to 70%
•    hemoglobin level below the lower level of normal
•    corrected calcium of more than 10 mg/dL (2.5 mmol/L)
•    lactate-dehydrogenase (LDH) level of more than 1.5-fold the upper 
level of normal
•    more than one organ system with metastasic lesions
Note: Three of the six criteria have to be fulfilled to classify patients suitable for 
temsirolimus therapy.OncoTargets and Therapy 2010:3 193
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nephrectomy eventually might not be essential to improve OS 
but prospective trials are pending.10–12 Thus the decision to 
perform debulking nephrectomy in synchronous metastatic 
poor-risk patients cannot be based on these results.
Clinical implications  
of temsirolimus treatment
Given the fact that angiogenic therapy suppresses tumor 
growth, we think therapy should be performed on a con-
tinuous basis until death. Even progression should not lead 
to a premature end of therapy, as rebound phenomena are 
commonly described. As temsirolimus is one of several 
available angiogenic drugs, major clinical problems are the 
control of its specific side effects, the criteria to determine the 
efficacy and the right indication for temsirolimus therapy.
Indication for temsirolimus
The OS benefit was shown in patients who were included 
based on a modified MSKCC risk classification, as shown in 
Tables 1 and 2. The difference between the risk classification 
systems derives mainly from the performance status and the 
number of organs harboring metastatic lesions. The “temsiro-
limus” criteria have not yet been validated and in all available 
risk profiles the number of metastatic organ systems has never 
been correlated with survival. Thus these criteria have to be 
interpreted thoroughly for selection of patients. As survival 
data for patients stratified according to the MSKCC criteria 
differ significantly, these so-called Motzer criteria are widely 
accepted in daily clinical practice. The difference between 
the Motzer criteria and the risk classification of the phase III 
temsirolimus trial is that in the temsirolimus trial the patients 
had to have a Karnofsky performance status between 60% 
and 70% and the amount of organs with metastatic lesions 
was included.
Reclassifying the temsirolimus high-risk patients into 
the MSKCC risk systems identifies 64 of 209 patients to be 
MSKCC intermediate-risk compared to 13 of 209 patients 
being intermediate-risk within the original study criteria.
In the MSKCC intermediate group the OS with IFN-
only therapy was 17.7 months compared to 13.0 months 
with temsirolimus treatment. In the MSKCC high-risk 
group OS was 6.0 months with IFN only and 10.2 months 
with temsirolimus. The difference was highly significant 
(P = 0.0014).
Therefore temsirolimus should be regarded a first-line 
standard in high-risk patients as identified by the 2004 
MSKCC risk criteria, as shown in Table 2.
indication in nonclear cell rCC
Approximately 80% of patients had clear cell RCC and 20% 
of patients had other histologies, the majority of which were 
papillary. Patients with clear cell and other RCC histologies, 
treated with temsirolimus, demonstrated comparable median 
OS and PFS superior to those treated with IFN alone. Median 
OS was 10.9 to 13.9 months in nonclear cell carcinomas with 
a PFS of 3.8 to 7.9 months related to the type of nonclear cell 
carcinoma. For patients treated with temsirolimus, 59% with 
clear cell and 68% with other RCC histologies experienced 
tumor reductions compared to 35% with clear cell and 14% 
with other RCC histologies having tumor reductions with 
IFN alone.13 Although sunitinib has shown some efficacy 
with a median PFS of 5.7 months in papillary RCC in a 
phase II trial, temsirolimus is the only drug with a analysis 
of patients with nonclear cell features in a phase III trial.14 
As a result of these phase III data temsirolimus remains the 
most efficacious drug in non-clear cell RCC histologies and 
might be regarded first choice in this subgroup of patients 
(NCCN guidelines).
Side effects and clinical handling
In the phase III study the most frequently occurring adverse 
events greater than grade three were asthenia, anemia and 
dyspnea. Other important side effects, although mostly 
grade 2 or less, were rash, stomatitis, diarrhea, vomiting 
and peripheral edema in about 20% to 30% of the cases. 
Hematologic toxicities and laboratory abnormalities were 
mainly grade 2 and included hyperlipidemia, hyperglycemia, 
hypercholesteremia, creatinine increase, thrombocytopenia 
and, mainly with combination treatment, neutropenia.
Rash, peripheral edema, hyperglycemia and hyperlipid-
emia were more common in the temsirolimus group, whereas 
asthenia was more common in the interferon group. There 
were fewer patients with serious adverse events in the tem-
sirolimus group than in the IFN group (P = 0.02).4
Table 2 Risk factors for the stratification of high-risk patients 
according to the Memorial Sloan Kettering Cancer Centre 
(MSKCC) risk classification8
•    disease-free interval (DFI) of less than a year
•    Karnofsky performance status less than 80%
•    hemoglobin level below the lower level of normal
•    corrected calcium of more than 10 mg/dL (2.5 mmol/L)
•    lactate-dehydrogenase (LDH) level of more than 1.5-fold the upper 
level of normalOncoTargets and Therapy 2010:3 194
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In daily practice, in more than 100 patients at our 
institution hyperlipidemia and thrombocytopenia are mostly 
clinically unimportant. Elevated creatinine levels might be 
related to peripheral edema and consecutive hypervolemic 
hypohydration. Thus diuretics should be started. Also hydro-
cortisone might be helpful to close capillary leaks and prevent 
a peripheral edema. In some cases even aggressive diuretic 
therapy might not overcome the situation. In this case therapy 
should be paused until re-compensation of the situation. 
Peripheral and pulmonary edema might lead to weight gain 
and dyspnea. Treatment should be done with diuretics and/
or hydrocortisone accordingly.
Hyperglycemia might be a problem if clinically symp-
tomatic. HbA1c values should be controlled regularly and 
if elevation persists with accompanying hyperglycemia 
anti-diabetes therapy should be started. The effect mainly is 
reversible when temsirolimus therapy is withdrawn.
Stomatitis and mucositis might not be easily diagnosed, 
as evident clinical signs are mainly lacking. Thus the 
patients often complain about pain without any recognizable 
lesion in the mouth. We have tried several mouth-rinsing 
lotions with or without local anesthetics but the best relief 
from the symptoms is achieved by sucking frozen pineapple 
pieces.
Therapy for rash is unnecessary in most patients. If 
needed, high-dose topical cortisone should be administered 
and might be combined with an antibiotic. Topical application 
of urea was not useful in our patients as it causes itching in 
most without relief of the rash.
A major problem for a minority of patients is fatigue. We 
have tried several treatments (such as testosterone, cortisone, 
physical exercise), but none was helpful. If the patient is 
really suffering from fatigue, it is important to talk to the 
relatives. Most partners of ill patients asked them to relax 
and to avoid any physical exercise. In doing so, fatigue is 
even intensified.
In a number of patients pneumonitis might be a problem. 
We have found several patients to show signs and symp-
toms of this infectious disease. The problem is that the 
pneumonitis might be regarded as progressive disease by 
some radiologists, thus resulting in a therapeutic switch. As 
shown in Figure 1, pneumonitis might show nodular changes, 
which easily can be misinterpreted as new metastatic lesions. 
Usually we treat patients with suspected pneumonitis with 
gyrase inhibitors (mainly moxifloxacin) with continued tem-
sirolimus treatment. Only in very severe cases is systemic 
mRCC therapy withdrawn after confirmation of the diagnosis 
by bronchoscopy and pulmonary lavage.
Most side effects are controllable and so far we have not 
needed to stop therapy due to side effects in any patient.
Evaluation of efficacy
PTEN and HIF1 alpha have been proposed as predictive 
biomarkers for temsirolimus treatment. In a substudy of 
the phase III protocol the baseline status of these molecules 
was determined and correlated to the clinical outcome of the 
patients. Unfortunately these levels did not correlate with 
efficacy in RCC patients treated with temsirolimus. Patients 
demonstrated OS and PFS benefit when treated with temsi-
rolimus regardless of PTEN and HIF1 alpha status.15
In daily treatment serum- or tissue-biomarkers are not used 
routinely. Therefore it might be beneficial to use information 
on tumor reassessments, mainly computed tomography (CT) 
scans, as biomarkers. It has been shown that angiogenic drugs 
reduce the blood flow in metastatic lesions within hours of 
administration, resulting in significant reduction in uptake 
of contrast media into lesions. This can be easily seen on the 
photographs of contrast media. Even quantification of the 
blood flow in these lesions is possible with modern radio-
logical scanners (Figure 2). Further investigation is needed to 
identify the changes in predictive biomarkers. But we already 
rely on the density of contrast media seen in the metastases 
on regular CT-printouts to determine the effect of the admin-
istered drug. As soon as the lesions gain perfusion compared 
to the lowest perfusion status achieved (low contrast media 
uptake), we consider switching the drug.
Discussion
Because of the recent approval of several drugs for the 
treatment of mRCC, several criteria must be considered 
when choosing the best drug for first-line therapy for the 
Figure 1 right-sided, ventral pneumonitis with temsirolimus treatment resembling 
new metastastic lesions.   After 10 days of antibiotic treatment the lesions faded away 
completely.OncoTargets and Therapy 2010:3 195
Temsirolimus for advanced renal cell carcinoma Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
individual patient. We know that most patients will be treated 
with sequenced therapeutic regimes based on several avail-
able drugs and drug classes.16 There is now evidence that 
administering targeted agents sequentially provides clinical 
benefit by inducing tumor shrinkage and prolonged PFS in a 
large number of patients. However, data on OS are still pend-
ing and will no longer be achievable in controlled trials. With 
many patients experiencing an OS of more than 40 months 
in sequenced therapeutic approaches, the situation of mRCC 
patients has dramatically improved.
The challenges of the future will be to identify the right 
patient for the right sequence. Based on several subgroup 
analyses, temsirolimus seems to provide its best results in 
patients younger than 65 years, with nonclear-cell histology 
and a MSKCC high-risk profile in non-nephrectomized 
patients.
Unfortunately no multi-variate analyses exist to reveal the 
best prognostic criteria to identify patients who will benefit 
from temsirolimus therapy in other settings.
Given the fact that a simple modification of the criteria 
to stratify patients as high risk versus intermediate risk, hints 
towards the possibility of finding even more sophisticated 
ways to identify the right patient for an efficacious temsiro-
limus treatment.
The clinical performance status seems to have a major 
impact on the effect of temsirolimus, as seen in the MSKCC 
criteria. But these criteria have been generated in patients who 
were treated mainly with chemotherapy and immunotherapy 
based on IFN. The identification of predictive risk factors 
for patients treated with angiogenic therapy is still pending. 
Surely not only clinical parameters but histological features 
should be considered.
We have found a subgroup of patients with good prognosis 
features who were initially tyrosine kinase inhibitor refractory 
but sensitive to temsirolimus therapy (data not shown). Future 
evaluation of first-line patients needs to discriminate between 
patients who are TKI-resistant but mTOR responders and 
those who are TKI responders. Also further studies should 
be undertaken to clarify the role of temsirolimus after TKI 
therapy.
Conclusion
Temsirolimus is the only drug for the treatment of mRCC 
that has a proven OS benefit over IFN alpha in high-risk 
patients. Thus in this group of patients temsirolimus is 
recommended as first-line standard. Side effects are control-
lable. Sequencing TKI therapy and temsirolimus should be 
evaluated in further protocols. There are suggestions that 
primary TKI-refractory patients might be treated effectively 
with temsirolimus. Further efforts should be undertaken to 
identify mTOR-sensitive and TKI-refractory patients prior 
to the beginning of first-line treatment.
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